Krystal Biotech Inc (KRYS) Stock Analysis
Verdict: BUY
High-margin VYJUVEK scaling and zero debt provide a floor, but aggressive insider selling and a recent revenue miss suggest a cooling period.
Investment score: 68/100
Analysis as of
Is Krystal Biotech Inc stock worth reviewing? The TradeMates thesis
Krystal Biotech is transitioning from a clinical-stage firm to a profitable cash-flow machine. While the recent revenue miss caused a sharp sell-off, the underlying fundamentals—specifically the 9.46 current ratio and lack of debt—remain elite for the biotech sector.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 95/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Krystal Biotech Inc opportunities and risks
What speaks for KRYS
- VYJUVEK International Expansion
What speaks against KRYS
- Persistent Insider Liquidation
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KRYS | 37.8x | 20.9x | 41.7x | 67.7% | 54.8% | 2.8% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.9% |
| APGE | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.8% |
| HALO | 28.2x | 6.5x | 18.6x | 76.9% | 23.1% | 6.8% |
| CYTK | n/a | 89.9x | n/a | 90.3% | -784.0% | -5.8% |
| IONS | n/a | 10.4x | 2.6x | 98.2% | -64.6% | -6.2% |
| Peer median | n/a | 6.5x | n/a | 76.9% | 0.0% | -3.9% |
Frequently asked questions about Krystal Biotech Inc (KRYS)
Is KRYS stock a good investment?
The TradeMates model rates Krystal Biotech Inc as BUY with an investment score of 68/100. Krystal Biotech is transitioning from a clinical-stage firm to a profitable cash-flow machine. While the recent revenue miss caused a sharp sell-off, the underlying fundamentals—specifically the 9.46 current ratio and lack of debt—remain elite for the biotech sector. This is algorithmic model output, not personal investment advice.
Is KRYS stock a buy?
The TradeMates model verdict for KRYS is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.